BidaskClub cut shares of AcelRx Pharmaceuticals (NASDAQ:ACRX) from a buy rating to a hold rating in a report released on Wednesday morning, BidAskClub reports.

Several other equities research analysts also recently commented on ACRX. Cantor Fitzgerald reiterated a buy rating and set a $9.00 target price on shares of AcelRx Pharmaceuticals in a report on Tuesday, December 11th. Oppenheimer reissued a hold rating on shares of AcelRx Pharmaceuticals in a research note on Tuesday, December 11th. HC Wainwright reiterated a buy rating and set a $9.00 target price on shares of AcelRx Pharmaceuticals in a report on Wednesday, December 12th. Zacks Investment Research upgraded AcelRx Pharmaceuticals from a sell rating to a hold rating in a report on Friday, December 14th. Finally, Credit Suisse Group started coverage on AcelRx Pharmaceuticals in a report on Friday, February 15th. They issued an outperform rating and a $7.00 price objective for the company. Two equities research analysts have rated the stock with a hold rating and nine have issued a buy rating to the company. The company currently has a consensus rating of Buy and a consensus target price of $7.84.

Shares of AcelRx Pharmaceuticals stock traded up $0.03 during trading hours on Wednesday, reaching $3.36. The stock had a trading volume of 7,081 shares, compared to its average volume of 1,766,647. The company has a market cap of $262.27 million, a price-to-earnings ratio of -4.14 and a beta of 2.15. The company has a debt-to-equity ratio of 0.79, a current ratio of 6.78 and a quick ratio of 6.73. AcelRx Pharmaceuticals has a 1 year low of $1.99 and a 1 year high of $5.05.

AcelRx Pharmaceuticals (NASDAQ:ACRX) last released its quarterly earnings data on Thursday, March 7th. The specialty pharmaceutical company reported ($0.18) EPS for the quarter, topping analysts’ consensus estimates of ($0.20) by $0.02. The firm had revenue of $0.61 million during the quarter, compared to analysts’ expectations of $3.10 million. Research analysts anticipate that AcelRx Pharmaceuticals will post -0.88 EPS for the current year.

In other AcelRx Pharmaceuticals news, Director Mark G. Edwards purchased 19,000 shares of AcelRx Pharmaceuticals stock in a transaction that occurred on Tuesday, March 12th. The stock was acquired at an average price of $2.99 per share, for a total transaction of $56,810.00. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders have purchased 26,721 shares of company stock valued at $78,506 in the last quarter. 25.50% of the stock is currently owned by corporate insiders.

A number of institutional investors have recently bought and sold shares of ACRX. First National Bank of Mount Dora Trust Investment Services bought a new position in AcelRx Pharmaceuticals in the first quarter valued at approximately $70,000. Raymond James & Associates grew its stake in shares of AcelRx Pharmaceuticals by 96.7% during the fourth quarter. Raymond James & Associates now owns 29,500 shares of the specialty pharmaceutical company’s stock worth $68,000 after buying an additional 14,500 shares during the last quarter. Two Sigma Advisers LP bought a new stake in shares of AcelRx Pharmaceuticals during the fourth quarter worth $89,000. Cedar Wealth Management LLC grew its stake in shares of AcelRx Pharmaceuticals by 36.9% during the fourth quarter. Cedar Wealth Management LLC now owns 46,395 shares of the specialty pharmaceutical company’s stock worth $107,000 after buying an additional 12,500 shares during the last quarter. Finally, Bank of New York Mellon Corp grew its stake in shares of AcelRx Pharmaceuticals by 55.1% during the fourth quarter. Bank of New York Mellon Corp now owns 67,149 shares of the specialty pharmaceutical company’s stock worth $155,000 after buying an additional 23,866 shares during the last quarter. Institutional investors and hedge funds own 18.69% of the company’s stock.

AcelRx Pharmaceuticals Company Profile

AcelRx Pharmaceuticals, Inc, a specialty pharmaceutical company, focuses on the development and commercialization of therapies for the treatment of acute pain. Its lead product candidate is DSUVIA, a 30 mcg sufentanil sublingual tablet for the treatment of moderate-to-severe acute pain. The company also develops ZALVISO, a pre-programmed and patient-controlled analgesia system that allows hospital patients with moderate-to-severe acute pain to self-dose with sufentanil sublingual tablets to manage their pain.

Featured Story: What are gap-down stocks?

Analyst Recommendations for AcelRx Pharmaceuticals (NASDAQ:ACRX)

Receive News & Ratings for AcelRx Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AcelRx Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.